Other

Biogen·Balance Sheet Statement·43 metrics

Breakdown

Loading...

Metrics

AOCI - Cash Flow Hedge Reclassification (Next 12 Months)

Cumulative Cost Basis

Fair Value Measurement Disclosure

Income taxes payable – long-term

Allowance for doubtful accounts

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Gross Unrealized Gains

Total

Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five

Due after five years

Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five

Due after five years

Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost

Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One

Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One

Available for sale investments

Common stock, par value (in dollars per share)

Deferred income taxes

Derivative Liability, Noncurrent

Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax

Gross Unrealized Gains

Cost

Finite-Lived Intangible Assets, Accumulated Amortization

2028

2030

2031

Remainder of 2026

2027

2029

Gross Carrying Amount

Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months

Goodwill accumulated impairment losses

Indefinite- lived intangible impairment

Inventory, Net Current and Noncurrent

Investment in biotechnology companies that are determined to be unconsolidated variable interest entities

Investments Fair Value Disclosure

Long Term Notes Payable

Plan Assets For Deferred Compensation Fair Value Disclosure

Preferred Stock, Par or Stated Value Per Share

Share of net profit from sage therapeutics, Percent

Valuation Allowances And Reserves Balance

Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2025